6855 Stock Overview
A clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Ascentage Pharma Group International Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$40.90 |
| 52 Week High | HK$48.85 |
| 52 Week Low | HK$15.42 |
| Beta | 1.1 |
| 11 Month Change | -13.99% |
| 3 Month Change | 42.51% |
| 1 Year Change | 66.94% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 86.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6855 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -3.8% | 2.2% | 1.6% |
| 1Y | 66.9% | -13.1% | 10.1% |
Return vs Industry: 6855 exceeded the Hong Kong Biotechs industry which returned -13.1% over the past year.
Return vs Market: 6855 exceeded the Hong Kong Market which returned 10.1% over the past year.
Price Volatility
| 6855 volatility | |
|---|---|
| 6855 Average Weekly Movement | 7.0% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in HK Market | 19.0% |
| 10% least volatile stocks in HK Market | 4.3% |
Stable Share Price: 6855 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 6855's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 574 | Dajun Yang | www.ascentage.cn |
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company’s primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin’s lymphoma.
Ascentage Pharma Group International Fundamentals Summary
| 6855 fundamental statistics | |
|---|---|
| Market cap | HK$12.67b |
| Earnings (TTM) | -HK$386.96m |
| Revenue (TTM) | HK$969.89m |
13.1x
P/S Ratio-32.8x
P/E RatioIs 6855 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6855 income statement (TTM) | |
|---|---|
| Revenue | CN¥903.03m |
| Cost of Revenue | CN¥27.45m |
| Gross Profit | CN¥875.58m |
| Other Expenses | CN¥1.24b |
| Earnings | -CN¥360.28m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.16 |
| Gross Margin | 96.96% |
| Net Profit Margin | -39.90% |
| Debt/Equity Ratio | 216.3% |
How did 6855 perform over the long term?
See historical performance and comparison